KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 73 filers reported holding KINNATE BIOPHARMA INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $512 | -15.0% | 81,967 | -17.0% | 0.00% | – |
| Q4 2022 | $602 | -100.0% | 98,706 | -11.1% | 0.00% | -100.0% |
| Q3 2022 | $1,327,000 | -5.3% | 111,053 | -0.0% | 0.00% | 0.0% |
| Q2 2022 | $1,401,000 | +51.5% | 111,085 | +20.8% | 0.00% | – |
| Q1 2022 | $925,000 | -41.9% | 91,945 | +2.3% | 0.00% | – |
| Q4 2021 | $1,593,000 | -27.7% | 89,876 | -6.0% | 0.00% | -100.0% |
| Q3 2021 | $2,202,000 | +63.8% | 95,636 | +65.6% | 0.00% | – |
| Q2 2021 | $1,344,000 | -12.3% | 57,743 | +17.4% | 0.00% | – |
| Q1 2021 | $1,532,000 | – | 49,186 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $225,156,000 | 30.44% |
| Vida Ventures Advisors, LLC | 2,747,433 | $63,960,000 | 16.04% |
| Foresite Capital Management V, LLC | 875,001 | $20,370,000 | 8.01% |
| VR Adviser, LLC | 1,473,014 | $34,292,000 | 4.16% |
| Logos Global Management LP | 1,329,602 | $30,953,000 | 2.60% |
| RA Capital Management | 3,593,052 | $83,646,000 | 1.34% |
| Orbimed Advisors | 3,847,929 | $89,580,000 | 0.91% |
| Boxer Capital, LLC | 1,065,939 | $24,815,000 | 0.88% |
| HARVARD MANAGEMENT CO INC | 498,001 | $11,593,000 | 0.67% |
| HighVista Strategies LLC | 33,391 | $777,000 | 0.55% |